Sign In
NASDAQ:ATRC
AtriCure Stock Earnings Reports
$32.01
-0.0700 (-0.218%)
At Close: Apr 17, 2025
AtriCure Earnings Calls
Q1 2025
(Upcoming)
| Release date | Apr 29, 2025 |
| EPS estimate | -$0.250 |
| EPS actual | - |
| Revenue estimate | 122.917M |
| Revenue actual | - |
| Expected change | +/- 4.27% |
Q4 2024
Beat
-$0.0800 (65.22%)
| Release date | Feb 12, 2025 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.0800 |
| EPS Surprise | 65.22% |
| Revenue estimate | 121.842M |
| Revenue actual | 124.277M |
| Revenue Surprise | 2.00% |
Q3 2024
Beat
-$0.170 (15.00%)
| Release date | Oct 29, 2024 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.170 |
| EPS Surprise | 15.00% |
| Revenue estimate | 119.85M |
| Revenue actual | 115.91M |
| Revenue Surprise | -3.29% |
Q2 2024
Missed
-$0.170 (-13.33%)
| Release date | Jul 30, 2024 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.170 |
| EPS Surprise | -13.33% |
| Revenue estimate | 116.18M |
| Revenue actual | 116.269M |
| Revenue Surprise | 0.0766% |
Last 4 Quarters for AtriCure
Below you can see how ATRC performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
| Release date | Jul 30, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $22.00 |
| EPS estimate | -$0.150 |
| EPS actual | -$0.170 |
| EPS surprise | -13.33% |
| Date | Price |
|---|---|
| Jul 24, 2024 | $23.99 |
| Jul 25, 2024 | $23.53 |
| Jul 26, 2024 | $22.10 |
| Jul 29, 2024 | $21.96 |
| Jul 30, 2024 | $22.00 |
| Jul 31, 2024 | $21.57 |
| Aug 01, 2024 | $21.04 |
| Aug 02, 2024 | $22.05 |
| Aug 05, 2024 | $21.43 |
| 4 days before | -8.30% |
| 4 days after | -2.59% |
| On release day | -1.95% |
| Change in period | -10.67% |
Q3 2024
Beat
| Release date | Oct 29, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $29.43 |
| EPS estimate | -$0.200 |
| EPS actual | -$0.170 |
| EPS surprise | 15.00% |
| Date | Price |
|---|---|
| Oct 23, 2024 | $28.85 |
| Oct 24, 2024 | $28.68 |
| Oct 25, 2024 | $27.93 |
| Oct 28, 2024 | $28.75 |
| Oct 29, 2024 | $29.43 |
| Oct 30, 2024 | $34.83 |
| Oct 31, 2024 | $33.18 |
| Nov 01, 2024 | $33.51 |
| Nov 04, 2024 | $33.66 |
| 4 days before | 2.01% |
| 4 days after | 14.37% |
| On release day | 18.35% |
| Change in period | 16.67% |
Q4 2024
Beat
| Release date | Feb 12, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $42.36 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.0800 |
| EPS surprise | 65.22% |
| Date | Price |
|---|---|
| Feb 06, 2025 | $40.96 |
| Feb 07, 2025 | $41.01 |
| Feb 10, 2025 | $42.02 |
| Feb 11, 2025 | $41.51 |
| Feb 12, 2025 | $42.36 |
| Feb 13, 2025 | $39.59 |
| Feb 14, 2025 | $40.94 |
| Feb 18, 2025 | $38.22 |
| Feb 19, 2025 | $39.01 |
| 4 days before | 3.42% |
| 4 days after | -7.91% |
| On release day | -6.54% |
| Change in period | -4.76% |
Q1 2025
(Upcoming)
| Release date | Apr 29, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | -$0.250 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 11, 2025 | $32.07 |
| Apr 14, 2025 | $32.62 |
| Apr 15, 2025 | $32.36 |
| Apr 16, 2025 | $32.08 |
| Apr 17, 2025 | $32.01 |
AtriCure Earnings Call Transcript Summary of Q4 2024
Q4 Revenue and Financial Overview
Q4 revenue reached $124.3 million, a growth of 16.6% compared to the same period in 2023.
- Profitability Improvement:
- Adjusted EBITDA improved from $19 million in 2023 to $31 million in 2024.
- The company also reported positive adjusted EBITDA of $12.7 million for Q4.
- Loss Per Share:
- Full year loss per share was $0.95, compared to $0.66 in the previous year.
- Adjusted loss per share for the year was $0.67.
Guidance for 2025
- Revenue Projection:
- AtriCure expects revenue for 2025 to be between $517 million and $527 million, indicating growth of 11% to 13% year-over-year.
- Adjusted EBITDA:
- The company anticipates adjusted EBITDA in the range of $42 million to $44 million, representing nearly 40% growth from 2024.
- Cash Generation:
- Expected moderate cash flow generation for 2025, with an initial cash burn likely in Q1 followed by positive cash flow in the remainder of the year.
Business Segment Performance
- Pain Management:
- Achieved 32% global growth in 2024 thanks to innovations like the cryoSPHERE+ and cryoSPHERE MAX probes, which reduce freeze times significantly.
- Continued efforts will focus on expanding the use of cryo nerve block therapy in various surgical procedures.
- Atrial Fibrillation Treatment:
- Open atrial fibrillation franchise growth slowed down due to PFA adoption pressures but remains a focus area with the EnCompass Clamp achieving 50% growth.
- Exploration of prophylactic ablation in non-AFib patients is underway with the new BoxX-NoAF clinical trial.
- Appendage Management:
- Continued strong performance with 16% growth in this segment, particularly with new product launches like the AtriClip FLEX-Mini, which is anticipated to fuel future growth.
Clinical and Product Development
- LeAAPS Clinical Trial: Currently enrolling to establish benefits of appendage management in patients undergoing cardiac surgery without pre-operative Afib; expected completion of enrollment by the end of 2025.
- New Product Initiatives: The company plans to explore additional indications for pain management technologies and expects growth opportunities from newer products and expanded market access in international regions.
Upcoming Events
- Investor Day: AtriCure will be hosting an Analyst and Investor Day on March 26, 2025, in Mason, Ohio, to present its product portfolio and growth strategies.
Overall, AtriCure demonstrated robust growth across its core franchises in 2024, with a strong outlook for 2025, driven by innovative products and continued market expansion. The company's strategic focus on both existing product lines and long-term clinical studies positions it well for sustained growth in the competitive medical device landscape.
AtriCure Earnings History
Earnings Calendar
FAQ
When is the earnings report for ATRC?
AtriCure (ATRC) has scheduled its earnings report for Apr 29, 2025 after the markets close.
What is the ATRC price-to-earnings (P/E) ratio?
ATRC P/E ratio as of Apr 17, 2025 (TTM) is -33.81.
What is the ATRC EPS forecast?
The forecasted EPS (Earnings Per Share) for AtriCure (ATRC) for the first fiscal quarter 2025 is -$0.250.
What are AtriCure's retained earnings?
On its balance sheet, AtriCure reported retained earnings of $124.28 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
